

2022 World Conference on Lung Cancer

August 6-9, 2022



You are entering a medical section of the Pfizer Landing Page. All materials here are presented for purposes of scientific exchange. They are NOT presented for any promotional purpose.

Pfizer Oral Presentations

OA15 - Patient Selection in Advanced NSCLC Immunotherapy

Tuesday, August 914:32–14:42 CEST

AvelumabOA15.03 / Abstract 698

Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis From JAVELIN Lung 100

Reck M

Presentation is sponsored by Merck as part of a strategic global alliance with Pfizer, Inc.

[View Presentation](#)

Pfizer ePosters

EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Saturday, August 6 –Tuesday, August 9ePosters will be available for viewing on the Virtual Platform

LorlatinibEP08.02-103 / Abstract 912

Lorlatinib for ALK+ NSCLC Patients Pretreated with Second-Generation ALK Inhibitors: Canadian Real-World Experience

Rupp M

[View Presentation](#)

LorlatinibEP08.02-115 / Abstract 826

A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan

Tamiya M

[View Presentation](#)

DacomitinibEP08.02-159 / Abstract 536

Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study

Wu L

[View Presentation](#)